AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02955810
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02955810
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02955810
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04440007
Drug: Abivertinib
RxNorm normalized name: Abivertinib
DrugBank: Abivertinib (DB15327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abivertinib maleate is a third-generation EGFR tyrosine kinase inhibitor and BTK Inhibitor. The starting dose is 200 mg p.o. QD for up to 28 days.
Trial: NCT04275388
Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
Trial: NCT03467386
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given CIV
Trial: NCT03683251
Drug: PDS Implant with Ranibizumab 100 mg/mL
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Will be administered as per the schedule described in individual arm
Trial: NCT03924986
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenously (IV) once every 3 weeks (Q3W)
Trial: NCT03924986
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gram per square meter of body surface area (g/m\^2) on Day 1 and day 8 of each cycle, administered as an IV infusion within 30 minutes, for 4 to 6 cycles
Trial: NCT03924986
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 milligrams per square meter of body surface area (mg/m\^2) on Day 1 of each cycle, administered as an IV infusion for over 4 hours if possible or with proper infusion time based on local clinical guidelines or clinical practice and according to the treating physician's clinical judgment, for 4 to 6 cycles.
Trial: NCT01428661
Drug: tasimelteon
RxNorm normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg once daily
Trial: NCT03105102
Drug: Placebo for Risankizumab SC
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for Risankizumab SC Subcutaneous (SC) Injection
Trial: NCT03105102
Drug: Risankizumab IV
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab IV Intravenous (IV) infusion
Trial: NCT03105102
Drug: Placebo for Risankizumab IV
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo for Risankizumab IV Intravenous (IV) infusion
Trial: NCT03105102
Drug: Risankizumab SC
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Risankizumab SC Subcutaneous (SC) injection
Trial: NCT03105102
Drug: Risankizumab On-Body Injector (OBI)
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) injection; on-body injector (OBI)
Trial: NCT00921765
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline single bolus dose followed by saline single bolus dose iv
Trial: NCT00921765
Drug: Saline + Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
Trial: NCT02736500
Drug: 28 GBq 177Lu-DOTATATE
RxNorm normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
Trial: NCT02736500
Drug: 22 GBq 177Lu-DOTATATE
RxNorm normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
Trial: NCT00921765
Drug: Naloxone + Placebo
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
Trial: NCT00921765
Drug: Naloxone + Ketamine
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
Trial: NCT03526185
Drug: Tumor Infiltrating Lymphocytes
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
Trial: NCT03526185
Drug: Nivolumab and Ipilimumab
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: • Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
Trial: NCT04948385
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: deep sedation with propofol +/- adjuvants such as midazolam, sufentanil, lidocaine and/or dehydrobenperidol
Trial: NCT00597727
Drug: Peanut SLIT
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
Trial: NCT01073059
Drug: Valproic acid and Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00877214
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
Trial: NCT00877214
Drug: Rituximab / observation
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
Trial: NCT04200781
Drug: Granules of Shengdi Dahuang Decoction
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Shengdi Dahuang Decoction contains Shengdi (rehmannia) and Dahuang ( rhubarb). Each pack of the granules of Shengdi Dahuang Decoction contains 15 grams of rehmannia and 5 grams of rhubarb.
Trial: NCT00666718
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Trial: NCT00666718
Drug: Insulin Lispro Protamine Suspension (ILPS)
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient glucose-level dependent, injection, once daily in the evening, 24 weeks
Trial: NCT00666718
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subcutaneous injections prior to meals, 24 weeks
Trial: NCT00246441
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
Trial: NCT00003119
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003119
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01165736
Drug: PF-05186462
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion of 100 microgram
Trial: NCT01165736
Drug: PF-05186462
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 100 microgram
Trial: NCT01165736
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion of 100 microgram of PF-05089771
Trial: NCT01165736
Drug: PF-05089771
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 100 microgram PF-05089771
Trial: NCT01165736
Drug: PF-05150122
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous administration of 100 microgram PF-05150122
Trial: NCT01165736
Drug: PF-05150122
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 100 microgram PF-05150122
Trial: NCT01165736
Drug: PF-05241328
RxNorm normalized name: PF-05241328
DrugBank: PF-05241328 (DB15124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intravenous infusion of 100 microgram PF-05241328
Trial: NCT01165736
Drug: PF-05241328
RxNorm normalized name: PF-05241328
DrugBank: PF-05241328 (DB15124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration 100 microgram PF-05241328
Trial: NCT03491709
Drug: anti-EGFR monoclonal antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
Trial: NCT03491709
Drug: Cetuximab injection
RxNorm normalized name: cetuximab Injection
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab injection
Trial: NCT04711668
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraoperative ketamine bolus and infusion
Trial: NCT04711668
Drug: Lidocain
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraoperative lidocain bolus and infusion
Trial: NCT04711668
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraoperative saline bolus and infusion
Trial: NCT00960310
Drug: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
RxNorm normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00960310
Drug: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
RxNorm normalized name: bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01578343
Drug: Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~2. Consolidation treatment for responders Patients not eligible for transplantation~   * Vorinostat maintenance up to 6 cycles~  * 200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~  * Delay of the start of the next cycle by up to 7 days will be acceptable.~  * If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~  * High-dose chemotherapy followed by autologous stem cell transplantation
Trial: NCT01368757
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen.
Trial: NCT01898117
Drug: Carbo/cyclo
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01898117
Drug: Carbo/cyclo + atezolizumab
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01898117
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01898117
Drug: Paclitaxel + Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00219544
Drug: Pregabalin (Lyrica)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin 150mg/day (75mg BID)
Trial: NCT00963599
Drug: Comparator: montelukast/loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Trial: NCT00963599
Drug: Comparator: montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: montelukast 10 mg tablet taken once daily at bed time for 2 weeks
Trial: NCT00963599
Drug: Comparator: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loratadine 10 mg tablet taken once daily at bed time for 2 weeks
Trial: NCT04658199
Drug: UCB0107 (bepranemab)
RxNorm normalized name: Immunoglobulin g4 (226-proline), anti-(human tau protein) (human-rattus norvegicus monoclonal ucb0107 .gamma.4-chain), disulfide with human-rattus norvegicus monoclonal ucb0107 .kappa.-chain, dimer
DrugBank: Bepranemab (DB17945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous
Trial: NCT02460133
Drug: Paritaprevir
RxNorm normalized name: Paritaprevir
DrugBank: Paritaprevir (DB09297)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02460133
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02460133
Drug: Dasabuvir
RxNorm normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02460133
Drug: Ombitasvir
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02460133
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
Trial: NCT00390793
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or IT
Trial: NCT00390793
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00390793
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT01958593
Drug: Midomafetamine
RxNorm normalized name: Midomafetamine
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MDMA-assisted therapy during two blinded experimental sessions. After unblinding, may receive a third session of open-label MDMA-assisted therapy.
Trial: NCT00390793
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00390793
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02858076
Drug: 2-mg Intravitreous Aflibercept Injection
RxNorm normalized name: aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
Trial: NCT00219544
Drug: Pregabalin (Lyrica)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin 300 mg/day (150mg BID)
Trial: NCT00219544
Drug: Pregabalin (Lyrica)
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin 600/day (300mg BID)
Trial: NCT00410592
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00410592
Drug: Pantoprazole 40mg
RxNorm normalized name: pantoprazole 40 MG
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00410592
Drug: Lansoprazole 30mg
RxNorm normalized name: LANSOPRAZOLE 30MG CAP,SA
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04199598
Drug: Abediterol (2.4 μg)
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Trial: NCT04199598
Drug: Abediterol (4.8 μg)
RxNorm normalized name: patiromer
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 μg (delivered dose) abediterol via PARI LC SPRINT nebuliser
Trial: NCT04199598
Drug: Abediterol (2.4 μg)
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 μg (delivered dose) abediterol via OMRON NE-C900-E nebuliser
Trial: NCT00203957
Drug: Istradefylline
RxNorm normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
Trial: NCT04199598
Drug: Abediterol (2.5 μg)
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg (nominal dose) abediterol via DPI, reference
Trial: NCT01958112
Drug: GSK1120212 (trametinib)
RxNorm normalized name: Tramétinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib dose is 1.5 mg orally once per day
Trial: NCT02376283
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02376283
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02376283
Drug: ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00056498
Drug: Risperdal
RxNorm normalized name: Risperdal
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperdal 4 mg per day for 16 weeks
Trial: NCT00814801
Drug: Galantamine 16 mg/day
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
Trial: NCT00814801
Drug: Galantamine 24 mg/day
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
Trial: NCT01141049
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
Trial: NCT03706222
Drug: elbasvir/grazoprevir
RxNorm normalized name: ELBASVIR/GRAZOPREVIR
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
Trial: NCT04238676
Drug: PP353
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: active administered by intradiscal injection
Trial: NCT00190684
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years